JANX - NASDAQ

Janux Therapeutics, Inc.

Janux Therapeutics, Inc.

JANXยทNASDAQ

$13.59

-1.4%
HealthcareBiotechnology

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$828.78M
EPS-1.8300
P/E Ratio-7.43
Earnings Date08/06/2026
Janux Therapeutics, Inc.

Janux Therapeutics, Inc. Fair Value Envelope

JANX ยท NASDAQ

Our analysis suggests that JANX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.59, this represents a potential HIDDEN relative to our calculated worth for Janux Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $13.59

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$71.0M
+ Cash & Equivalents$52.3M
Firm Value-$18.7M
- Debt$22.1M
Equity Value-$40.8M
/ Shares Outstanding60,146,750B
DCF Value-$1
OVERVALUED BY 105%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$41.1M
-$20.6M
-$10.3M
-$5.1M
-$2.6M
-$1.3M
-$642.5K
-$321.2K
-$160.6K
-$80.3K
Maintenance CapEx
-$104.3K
-$52.2K
-$26.1K
-$13.0K
-$6.5K
-$3.3K
-$1.6K
-$815
-$407
-$204
Owner Earnings
-$41.2M
-$20.6M
-$10.3M
-$5.2M
-$2.6M
-$1.3M
-$644.1K
-$322.0K
-$161.0K
-$80.5K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$38.2M
-$17.7M
-$8.2M
-$3.8M
-$1.8M
-$811.8K
-$375.8K
-$174.0K
-$80.6K
-$37.3K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your JANX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.